- Home
- / ChemoCentryx
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
ChemoCentryx financials data including stock price, CreditSafe score, income statement, balance sheet, cash flow, and acquistions and subsidiaries.
Revenue
$32.2 M
FY, 2021
CreditSafe Score
?
Score changed on Jun 05, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|
| Revenue | 36.1M | 64.9M | 32.2M |
| Revenue growth, % | -15.7% | 79.6% | |
| Cost of goods sold | 302.0K | ||
| Gross profit | 31.9M | ||
| Gross profit margin, % | 99.1% | ||
| General and administrative expense | 24.2M | 42.2M | 78.9M |
| Operating expense total | 94.4M | 120.1M | 161.8M |
| EBIT | (58.3M) | (55.2M) | (129.9M) |
| EBIT margin, % | -161.4% | -85.0% | -403.2% |
| Interest income | 5.0M | 2.5M | 859.0K |
| Interest expense | 2.1M | 2.6M | 2.7M |
| Net Income | (55.5M) | (55.4M) | (131.8M) |
| EPS | (1.0) | (0.8) | (1.9) |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |